Analysis Tools
cardiovascular system
|
• after 6 months of age
|
|
• at 200 days, mice exhibit increased left ventricular chamber size compared with wild-type mice
|
|
• mild at 6 months
• severe at 9 months
|
dilated heart
(
J:86400
)
|
• after 6 months of age
|
|
• doxorubicin-treated mice exhibit a greater decrease in cardiac systolic function compared with similarly treated wild-type mice
|
|
• at 200 days
|
|
• after 6 months of age
|
immune system
|
• in the cardiac myocytes of LPS-treated mice
|
|
• LPS-treated mice exhibit increased myocyte apoptosis and TNF-alpha levels in cardiac myocytes compared with similarly treated wild-type mice
|
homeostasis/metabolism
|
• doxorubicin-treated mice exhibit a greater decrease in cardiac systolic function compared with similarly treated wild-type mice
|
respiratory system
|
• after 6 months of age
|
growth/size/body
|
• after 6 months of age
|
muscle
|
• at 200 days
|
|
• LPS-treated mice exhibit increased myocyte apoptosis compared with similarly treated wild-type mice
|
cellular
|
• LPS-treated mice exhibit increased myocyte apoptosis compared with similarly treated wild-type mice
|
